Prognostic and predictive value of intratumoral microvessels density in operable non-small-cell lung cancer

Claudio Dazzi, Anna Cariello, Patrizia Maioli, Luciano Solaini, Emanuela Scarpi, Giovanni Rosti, Giuseppe Lanzanova, Maurizio Marangolo

Research output: Contribution to journalArticle

Abstract

Experimental evidence suggests that tumor growth and progression depend on angiogenesis. In a retrospective study we evaluated the relationship between tumor angiogenesis and survival in patients with NSCLC treated with potentially curative surgery between 1992 and 1997. The study population consisted of 76 patients. An anti-CD34 monoclonal antibody was used to measure angiogenesis in tumor samples. Angiogenesis was quantified in terms of microvessel count (MVC): in each sample the three most intense regions of neovascularization were identified under low microscopic power. A x 250 field in each of the three areas was then counted and the highest count of the three fields was recorded. Disease free (DFS) and overall survival (OS) during follow up were evaluated. Gender, age, stage, histologic type and KI-67 were the other factors considered for analysis. The median MVC in our series was 41.5. Among the clinicopathologic parameters examined the microvessel count was the only one to show a significant association with disease free survival in univariate analysis (P = 0.04). MVC value is a new indicator of tumor aggressiveness in patients with NSCLC who underwent potentially curative surgery and should be taken into consideration in selecting patients for adjuvant treatment.

Original languageEnglish
Pages (from-to)81-88
Number of pages8
JournalLung Cancer
Volume24
Issue number2
DOIs
Publication statusPublished - May 1999

Fingerprint

Microvessels
Non-Small Cell Lung Carcinoma
Neoplasms
Survival
Statistical Factor Analysis
Disease-Free Survival
Retrospective Studies
Monoclonal Antibodies
Growth
Population
Therapeutics

Keywords

  • Angiogenesis
  • Metastases
  • Microvessel count
  • Non-small-cell lung cancer
  • Prognostic factor

ASJC Scopus subject areas

  • Oncology

Cite this

Prognostic and predictive value of intratumoral microvessels density in operable non-small-cell lung cancer. / Dazzi, Claudio; Cariello, Anna; Maioli, Patrizia; Solaini, Luciano; Scarpi, Emanuela; Rosti, Giovanni; Lanzanova, Giuseppe; Marangolo, Maurizio.

In: Lung Cancer, Vol. 24, No. 2, 05.1999, p. 81-88.

Research output: Contribution to journalArticle

Dazzi, C, Cariello, A, Maioli, P, Solaini, L, Scarpi, E, Rosti, G, Lanzanova, G & Marangolo, M 1999, 'Prognostic and predictive value of intratumoral microvessels density in operable non-small-cell lung cancer', Lung Cancer, vol. 24, no. 2, pp. 81-88. https://doi.org/10.1016/S0169-5002(99)00036-7
Dazzi, Claudio ; Cariello, Anna ; Maioli, Patrizia ; Solaini, Luciano ; Scarpi, Emanuela ; Rosti, Giovanni ; Lanzanova, Giuseppe ; Marangolo, Maurizio. / Prognostic and predictive value of intratumoral microvessels density in operable non-small-cell lung cancer. In: Lung Cancer. 1999 ; Vol. 24, No. 2. pp. 81-88.
@article{cf351167410a488dbd0900c279c8ea81,
title = "Prognostic and predictive value of intratumoral microvessels density in operable non-small-cell lung cancer",
abstract = "Experimental evidence suggests that tumor growth and progression depend on angiogenesis. In a retrospective study we evaluated the relationship between tumor angiogenesis and survival in patients with NSCLC treated with potentially curative surgery between 1992 and 1997. The study population consisted of 76 patients. An anti-CD34 monoclonal antibody was used to measure angiogenesis in tumor samples. Angiogenesis was quantified in terms of microvessel count (MVC): in each sample the three most intense regions of neovascularization were identified under low microscopic power. A x 250 field in each of the three areas was then counted and the highest count of the three fields was recorded. Disease free (DFS) and overall survival (OS) during follow up were evaluated. Gender, age, stage, histologic type and KI-67 were the other factors considered for analysis. The median MVC in our series was 41.5. Among the clinicopathologic parameters examined the microvessel count was the only one to show a significant association with disease free survival in univariate analysis (P = 0.04). MVC value is a new indicator of tumor aggressiveness in patients with NSCLC who underwent potentially curative surgery and should be taken into consideration in selecting patients for adjuvant treatment.",
keywords = "Angiogenesis, Metastases, Microvessel count, Non-small-cell lung cancer, Prognostic factor",
author = "Claudio Dazzi and Anna Cariello and Patrizia Maioli and Luciano Solaini and Emanuela Scarpi and Giovanni Rosti and Giuseppe Lanzanova and Maurizio Marangolo",
year = "1999",
month = "5",
doi = "10.1016/S0169-5002(99)00036-7",
language = "English",
volume = "24",
pages = "81--88",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Prognostic and predictive value of intratumoral microvessels density in operable non-small-cell lung cancer

AU - Dazzi, Claudio

AU - Cariello, Anna

AU - Maioli, Patrizia

AU - Solaini, Luciano

AU - Scarpi, Emanuela

AU - Rosti, Giovanni

AU - Lanzanova, Giuseppe

AU - Marangolo, Maurizio

PY - 1999/5

Y1 - 1999/5

N2 - Experimental evidence suggests that tumor growth and progression depend on angiogenesis. In a retrospective study we evaluated the relationship between tumor angiogenesis and survival in patients with NSCLC treated with potentially curative surgery between 1992 and 1997. The study population consisted of 76 patients. An anti-CD34 monoclonal antibody was used to measure angiogenesis in tumor samples. Angiogenesis was quantified in terms of microvessel count (MVC): in each sample the three most intense regions of neovascularization were identified under low microscopic power. A x 250 field in each of the three areas was then counted and the highest count of the three fields was recorded. Disease free (DFS) and overall survival (OS) during follow up were evaluated. Gender, age, stage, histologic type and KI-67 were the other factors considered for analysis. The median MVC in our series was 41.5. Among the clinicopathologic parameters examined the microvessel count was the only one to show a significant association with disease free survival in univariate analysis (P = 0.04). MVC value is a new indicator of tumor aggressiveness in patients with NSCLC who underwent potentially curative surgery and should be taken into consideration in selecting patients for adjuvant treatment.

AB - Experimental evidence suggests that tumor growth and progression depend on angiogenesis. In a retrospective study we evaluated the relationship between tumor angiogenesis and survival in patients with NSCLC treated with potentially curative surgery between 1992 and 1997. The study population consisted of 76 patients. An anti-CD34 monoclonal antibody was used to measure angiogenesis in tumor samples. Angiogenesis was quantified in terms of microvessel count (MVC): in each sample the three most intense regions of neovascularization were identified under low microscopic power. A x 250 field in each of the three areas was then counted and the highest count of the three fields was recorded. Disease free (DFS) and overall survival (OS) during follow up were evaluated. Gender, age, stage, histologic type and KI-67 were the other factors considered for analysis. The median MVC in our series was 41.5. Among the clinicopathologic parameters examined the microvessel count was the only one to show a significant association with disease free survival in univariate analysis (P = 0.04). MVC value is a new indicator of tumor aggressiveness in patients with NSCLC who underwent potentially curative surgery and should be taken into consideration in selecting patients for adjuvant treatment.

KW - Angiogenesis

KW - Metastases

KW - Microvessel count

KW - Non-small-cell lung cancer

KW - Prognostic factor

UR - http://www.scopus.com/inward/record.url?scp=0032807992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032807992&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(99)00036-7

DO - 10.1016/S0169-5002(99)00036-7

M3 - Article

C2 - 10444058

AN - SCOPUS:0032807992

VL - 24

SP - 81

EP - 88

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -